Over the last decade international and national
rules have been amended to develop a tough
stance against transnational bribery, and
as a result legal and reputational risks
for the pharmaceutical industry - as for
other sectors - have risen considerably.
Specifically in the pharmaceutical sector
several areas appear particularly problematic:
There have been cases of manipulated research,
of undue influence on licensing and listing;
corruption has been noticed in the context
of production and logistics and finally
the pressure to exert undue influence is
certainly strong in promotional activities.
Changing "the rules of the game"
is, however, not exclusively a matter for
the public sector. The private sector is
well placed to develop the details of how
to conduct business with third parties (agents,
subsidiaries, joint venture partners) without
running the risk of being misused.
In many areas of the world corruption
is still endemic and the pharmaceutical
industry has not been left untouched by
the issue. Over the last decade international
and national rules have been amended to
develop a tough stance, especially against
transnational bribery.
Topics:
1. Putting the problems on the table:
How does corruption manifest itself in
this industry?
2. A risk analysis of the issues at stake.
3. The feasibility of a common standard
for the pharmaceutical industry.
4. Next steps to realising an industry
standard
|
Coordinator
:
